Implementation of pre‐emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand?
E Peruzzi, R Roncato, E De Mattia… - British Journal of …, 2023 - Wiley Online Library
Adverse drug reactions (ADRs) account for a large proportion of hospitalizations among
adults and are more common in multimorbid patients, worsening clinical outcomes and …
adults and are more common in multimorbid patients, worsening clinical outcomes and …
Survival of Patients With Cancer With DPYD Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy—A Matched-Pair Analysis
JE Knikman, TA Wilting, M Lopez-Yurda… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE DPYD-guided fluoropyrimidine dosing improves patient safety in carriers of
DPYD variant alleles. However, the impact on treatment outcome in these patients is largely …
DPYD variant alleles. However, the impact on treatment outcome in these patients is largely …
Pharmacogenetics in Oncology: A useful tool for individualizing drug therapy
R Nogueiras‐Álvarez… - British Journal of Clinical …, 2024 - Wiley Online Library
With the continuous development of genetics in healthcare, there has been a significant
contribution to the development of precision medicine, which is ultimately aimed at …
contribution to the development of precision medicine, which is ultimately aimed at …
Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis
G Le Teuff, N Cozic, JC Boyer, V Boige… - British journal of …, 2024 - nature.com
Background Dihydropyrimidine dehydrogenase (DPD) deficiency is the main known cause
of life-threatening fluoropyrimidine (FP)-induced toxicities. We conducted a meta-analysis on …
of life-threatening fluoropyrimidine (FP)-induced toxicities. We conducted a meta-analysis on …
Clinical benefits and utility of pretherapeutic DPYD and UGT1A1 testing in gastrointestinal cancer: a secondary analysis of the PREPARE randomized clinical trial
R Roncato, A Bignucolo, E Peruzzi… - JAMA Network …, 2024 - jamanetwork.com
Importance To date, the clinical benefit and utility of implementing aDPYD/
UGT1A1pharmacogenetic-informed therapy with fluoropyrimidines and/or irinotecan have …
UGT1A1pharmacogenetic-informed therapy with fluoropyrimidines and/or irinotecan have …
Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementation
Background: Awareness about the importance of implementing DPYD pharmacogenetics in
clinical practice to prevent severe side effects related to the use of fluoropyrimidines has …
clinical practice to prevent severe side effects related to the use of fluoropyrimidines has …
Updated DPYD HapB3 haplotype structure and implications for pharmacogenomic testing
The DPYD gene encodes dihydropyrimidine dehydrogenase, the rate‐limiting enzyme for
the metabolism of fluoropyrimidines 5‐fluorouracil and capecitabine. Genetic variants in …
the metabolism of fluoropyrimidines 5‐fluorouracil and capecitabine. Genetic variants in …
Real-World Impact of an In-House Dihydropyrimidine Dehydrogenase (DPYD) Genotype Test on Fluoropyrimidine Dosing, Toxicities, and Hospitalizations at a …
DG Nguyen, SA Morris, A Hamilton… - JCO Precision …, 2024 - ascopubs.org
PURPOSE Fluoropyrimidine-related toxicity and mortality risk increases significantly in
patients carrying certain DPYD genetic variants with standard dosing. We implemented …
patients carrying certain DPYD genetic variants with standard dosing. We implemented …
Pharmacogenetics of DPYD and treatment-related mortality on fluoropyrimidine chemotherapy for cancer patients: a meta-analysis and trial sequential analysis
FCA de Moraes, AB de Almeida Barbosa, VKT Sano… - BMC cancer, 2024 - Springer
Background Fluoropyrimidines are chemotherapy drugs utilized to treat a variety of solid
tumors. These drugs predominantly rely on the enzyme dihydropyrimidine dehydrogenase …
tumors. These drugs predominantly rely on the enzyme dihydropyrimidine dehydrogenase …
Development of a multifaceted program for pharmacogenetics adoption at an academic medical center: practical considerations and lessons learned
T Shugg, EM Tillman, AM Breman… - Clinical …, 2024 - Wiley Online Library
In 2019, Indiana University launched the Precision Health Initiative to enhance the
institutional adoption of precision medicine, including pharmacogenetics (PGx) …
institutional adoption of precision medicine, including pharmacogenetics (PGx) …